Tumor growth was also suppressed by inhibiting BMI1 pharmacologically in HNSCC and targeting BMI1 related CSC in oral squamous cell carcinoma (OSCC) has been shown as a clinically relevant anticancer therapy [41,42]. This evidence concerns the gene BMI1 and neoplasm.